RAB11FIP1
gene geneOn this page
Also known as RCPFLJ22622FLJ22524Rab11-FIP1
Summary
RAB11FIP1 (RAB11 family interacting protein 1, HGNC:30265) is a protein-coding gene on chromosome 8p11.23, encoding Rab11 family-interacting protein 1 (Q6WKZ4). A Rab11 effector protein involved in the endosomal recycling process.
This gene encodes one of the Rab11-family interacting proteins (Rab11-FIPs), which play a role in the Rab-11 mediated recycling of vesicles. The encoded protein may be involved in endocytic sorting, trafficking of proteins including integrin subunits and epidermal growth factor receptor (EGFR), and transport between the recycling endosome and the trans-Golgi network. Alternative splicing results in multiple transcript variants. A pseudogene is described on the X chromosome.
Source: NCBI Gene 80223 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 214 total
- MANE Select transcript:
NM_001002814
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:30265 |
| Approved symbol | RAB11FIP1 |
| Name | RAB11 family interacting protein 1 |
| Location | 8p11.23 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | RCP, FLJ22622, FLJ22524, Rab11-FIP1 |
| Ensembl gene | ENSG00000156675 |
| Ensembl biotype | protein_coding |
| OMIM | 608737 |
| Entrez | 80223 |
Gene structure
Transcript identifiers
Ensembl transcripts: 9 — 7 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined
ENST00000287263, ENST00000330843, ENST00000522727, ENST00000522774, ENST00000523182, ENST00000524118, ENST00000882279, ENST00000966921, ENST00000966922
RefSeq mRNA: 2 — MANE Select: NM_001002814
NM_001002814, NM_025151
CCDS: CCDS34881, CCDS34882
Canonical transcript exons
ENST00000330843 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001236275 | 37874515 | 37875322 |
| ENSE00001312334 | 37871278 | 37873179 |
| ENSE00002104955 | 37899071 | 37899497 |
| ENSE00002112214 | 37858618 | 37863113 |
| ENSE00003499699 | 37870420 | 37870528 |
| ENSE00003636778 | 37877109 | 37877551 |
Expression profiles
Bgee: expression breadth ubiquitous, 273 present calls, max score 99.28.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.6572 / max 1145.3604, expressed in 1510 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 92718 | 23.6572 | 1510 |
Top tissues by expression
286 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| esophagus squamous epithelium | UBERON:0006920 | 99.28 | gold quality |
| lower lobe of lung | UBERON:0008949 | 97.91 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 97.87 | gold quality |
| amniotic fluid | UBERON:0000173 | 96.94 | gold quality |
| bronchial epithelial cell | CL:0002328 | 96.73 | gold quality |
| oral cavity | UBERON:0000167 | 96.50 | gold quality |
| islet of Langerhans | UBERON:0000006 | 96.49 | gold quality |
| squamous epithelium | UBERON:0006914 | 96.29 | gold quality |
| jejunal mucosa | UBERON:0000399 | 95.89 | gold quality |
| ileal mucosa | UBERON:0000331 | 95.79 | gold quality |
| colonic mucosa | UBERON:0000317 | 95.74 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 95.60 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 95.55 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 95.30 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 95.28 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 95.13 | gold quality |
| epithelium of bronchus | UBERON:0002031 | 95.07 | gold quality |
| bronchus | UBERON:0002185 | 94.97 | gold quality |
| rectum | UBERON:0001052 | 94.07 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 93.97 | gold quality |
| upper leg skin | UBERON:0004262 | 93.96 | gold quality |
| duodenum | UBERON:0002114 | 93.92 | gold quality |
| blood | UBERON:0000178 | 93.20 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 93.04 | gold quality |
| decidua | UBERON:0002450 | 93.03 | gold quality |
| bone marrow | UBERON:0002371 | 92.91 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 92.40 | gold quality |
| monocyte | CL:0000576 | 92.27 | gold quality |
| trachea | UBERON:0003126 | 92.26 | gold quality |
| lung | UBERON:0002048 | 92.24 | gold quality |
Single-cell (SCXA)
Detected in 11 experiment(s), a significant marker in 10.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-114 | yes | 54.32 |
| E-HCAD-6 | yes | 44.85 |
| E-MTAB-10287 | yes | 40.98 |
| E-MTAB-9467 | yes | 22.37 |
| E-CURD-122 | yes | 12.84 |
| E-GEOD-135922 | yes | 10.40 |
| E-GEOD-130148 | yes | 9.56 |
| E-CURD-46 | yes | 9.46 |
| E-MTAB-6678 | yes | 7.72 |
| E-CURD-89 | no | 335.80 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
223 targeting RAB11FIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-3925-3P | 100.00 | 69.95 | 1237 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-1184 | 99.99 | 68.19 | 1458 |
| HSA-MIR-27A-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-27B-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-9985 | 99.98 | 72.11 | 2939 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-302C-5P | 99.97 | 72.56 | 3642 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-302E | 99.96 | 70.74 | 2669 |
| HSA-MIR-6778-3P | 99.96 | 67.29 | 2693 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-551B-5P | 99.96 | 71.28 | 3493 |
| HSA-MIR-128-3P | 99.95 | 71.17 | 2484 |
| HSA-MIR-216A-3P | 99.95 | 71.19 | 2505 |
| HSA-MIR-144-3P | 99.94 | 73.98 | 2698 |
| HSA-MIR-101-3P | 99.94 | 75.03 | 2230 |
Literature-anchored findings (GeneRIF, showing 36)
- Rab coupling protein (RCP), a novel Rab4 and Rab11 effector protein (PMID:11786538)
- Receptor cell surface expression and endocytosis experiments reveal that the small GTPase Rab11 protein is a determinant factor in controlling thromboxane A2 receptor beta isoform recycling back to the cell surface. (PMID:15134434)
- RCP functions primarily as a Rab11 binding protein that regulates protein sorting in tubular endosomes. (PMID:15181150)
- Rab11, rather than Rab4, mediates the intracellular localisation of RCP. (PMID:15280022)
- Acting as an intermediate between Rab4 and Rab11, RCP regulates membrane flux along the phagocytic pathway via recycling events. (PMID:15355514)
- once the Rab11/RCP-regulated cargo has been delivered from the endocytic recycling compartment to the plasma membrane, RCP is inactivated by calpain-mediated proteolysis (PMID:15769254)
- Rab11 and microtubules maintain the proper distribution of the subapical AQP2 storage compartment, and actin filaments regulate the trafficking of AQP2 from early endosomes to the storage compartment. (PMID:16049696)
- Results describe the endometrial expression of Rab coupling protein and its hormonal regulation. (PMID:16216915)
- identified eight alternatively spliced Rab11-FIP1 gene transcripts from human chromosome 8 (PMID:16920206)
- RCP provides a scaffold that promotes the physical association and coordinate trafficking of alpha5beta1 and EGFR1 and that this drives migration of tumor cells into three-dimensional matrices. (PMID:18838556)
- RCP is a human breast cancer-promoting gene with Ras-activating function. (PMID:19620787)
- FIP1/RCP binding to Golgin-97 is required for tethering and fusion of recycling endosome-derived retrograde transport vesicles to the trans-Golgi network. (PMID:20610657)
- An interaction with Rab11 is necessary for long-range targeting of beta1 integrins to the growth cone along axons and in neurons. (PMID:20810886)
- results suggest that Rab5 is involved in CB2 endocytosis and that internalized receptors are recycled via a Rab11 associated pathway rather than the rapid Rab4 associated pathway. (PMID:21640764)
- Rab11 is differentially phosphorylated by distinct PKC isoenzymes; this post-translational modification might be a regulatory mechanism of intracellular trafficking. (PMID:22188018)
- These findings suggest that Rab11-FIP1 proteins participate in spatially and temporally distinct steps of the recycling process along a complex and dynamic tubular network in which Rab11-FIPs occupy discrete domains (PMID:23283983)
- findings support a model for HIV-1 Env incorporation in which specific targeting to the particle assembly microdomain on the plasma membrane is mediated by FIP1C and Rab14 (PMID:23592992)
- rab11 effector protein FIP1 regulates adiponectin trafficking and secretion (PMID:24040321)
- Mitochondrial remodeling was associated with increased proximity between Rab11a and mitochondrial membranes, changes in fusion-fission dynamics, and mitochondrial relocalization of the Drp1, which was regulated by the Rab11a effector protein FIP1/RCP. (PMID:24302731)
- We find that Rab14 indeed binds to RCP, albeit with reduced affinity relative to conventional Rab11-FIP and Rab25-FIP complexes. However, in vivo, Rab11 recruits RCP onto biological membranes. (PMID:26032412)
- GTPase Rab11, but not Rab4, is involved in the recycling of hERG channels. (PMID:26152716)
- REI/SH3BP5 protein family is conserved in evolution and is a group of new guanine nucleotide exchange factors for Rab11. (PMID:26745340)
- Rab11-FIP1A associates with and regulates trafficking at an early step in the process of membrane recycling (PMID:26790954)
- our findings indicate that FIP1C acts as a tumor suppressor in the context of ErbB2-positive breast cancer (PMID:26933086)
- Findings suggest that overexpression of micro ribonucleic acid-93 (miR-93) via targeting RAB11 family interacting protein (RAB11FIP1) as an early event plays an important role in oncogenesis of cervical cancer. MiR-93 and its target protein RAB11FIP1 may be potential therapeutic targets for cervical cancer and its precursors. (PMID:27279231)
- High RCP expression is associated with lung metastasis in ovarian cancer. (PMID:27524413)
- The article focuses on the latest advances regarding the mechanisms that ensure the compartmentalized regulation of Rab11 function through its interaction with phosphoinositides. (Review) (PMID:27658318)
- Phosphorylation of RCP at Ser(435) by Lemur tyrosine kinase-3 (LMTK3) and of EphA2 at Ser(897) by Akt are both necessary to promote Rab14-dependent (and Rab11-independent) trafficking of EphA2 which generates cell:cell repulsion events that drive tumour cells apart. (PMID:28294115)
- The findings thus define that delivery of recycling cargo toward the ERC requires spatial and sequential coupling of Rab11 activity with PtdIns(3)P turnover. (PMID:29915378)
- Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90alpha Secretion. (PMID:32640214)
- Zeb1 for RCP-induced oral cancer cell invasion and its suppression by resveratrol. (PMID:32728068)
- Thrombin-activated PAR1 membrane expression is regulated by Rab11a-RCP complex dissociation. (PMID:32860953)
- Rab11FIP1 maintains Rab35 at the intercellular bridge to promote actin removal and abscission. (PMID:34152390)
- Rab11-FIP1 and Rab11-FIP5 Regulate pIgR/pIgA Transcytosis through TRIM21-Mediated Polyubiquitination. (PMID:34638806)
- Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4[+] T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines. (PMID:36354340)
- microRNA-205 represses breast cancer metastasis by perturbing the rab coupling protein [RCP]-mediated integrin beta1 recycling on the membrane. (PMID:37945815)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rab11fip1a | ENSDARG00000046124 |
| mus_musculus | Rab11fip1 | ENSMUSG00000031488 |
| rattus_norvegicus | Rab11fip1 | ENSRNOG00000058940 |
| drosophila_melanogaster | Rip11 | FBGN0027335 |
| caenorhabditis_elegans | WBGENE00021456 |
Paralogs (2): RAB11FIP2 (ENSG00000107560), RAB11FIP5 (ENSG00000135631)
Protein
Protein identifiers
Rab11 family-interacting protein 1 — Q6WKZ4 (reviewed: Q6WKZ4)
Alternative names: Rab-coupling protein
All UniProt accessions (2): Q6WKZ4, E7EX40
UniProt curated annotations — full annotation on UniProt →
Function. A Rab11 effector protein involved in the endosomal recycling process. Also involved in controlling membrane trafficking along the phagocytic pathway and in phagocytosis. Interaction with RAB14 may function in the process of neurite formation.
Subunit / interactions. Interacts with RAB11A (GTP-bound form); the interaction induces RAB11FIP1 recruitment to membranes. Interacts with RAB14 (GTP-bound form). Homooligomer. Isoform 2 interacts with RAB4A, RAB11A, RAB11B and RAB25. According to PubMed:15280022, RAB4A binding to RAB11FIP1 is of very low affinity in vitro and in vivo.
Subcellular location. Recycling endosome. Cytoplasmic vesicle Cytoplasmic vesicle. Phagosome membrane.
Tissue specificity. Isoform 2 is expressed in brain, heart, testis, lung, spleen, ovary and small intestine.
Domain organisation. The FIP-RBD is involved in the interaction with Rab proteins.
Isoforms (5)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6WKZ4-4 | 1, Rab11-FIP 1B | yes |
| Q6WKZ4-3 | 2, Rab11-FIP 1C | |
| Q6WKZ4-1 | 3, Rab11-FIP 1A | |
| Q6WKZ4-2 | 4, Rab11-FIP 1H, No Rab11-binding protein 2 | |
| Q6WKZ4-5 | 5 |
RefSeq proteins (2): NP_001002814, NP_079427 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000008 | C2_dom | Domain |
| IPR019018 | Rab-bd_FIP-RBD | Domain |
| IPR035892 | C2_domain_sf | Homologous_superfamily |
| IPR037245 | FIP-RBD_C_sf | Homologous_superfamily |
| IPR037789 | FIP_classI | Family |
Pfam: PF00168, PF09457
UniProt features (67 total): modified residue 19, compositionally biased region 13, sequence conflict 9, region of interest 7, splice variant 7, sequence variant 4, mutagenesis site 3, domain 2, helix 2, chain 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 4D0G | X-RAY DIFFRACTION | 2.5 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6WKZ4-F1 | 47.19 | 0.10 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (19): 184, 202, 206, 234, 300, 315, 339, 341, 343, 345, 356, 357, 382, 435, 477, 529, 545, 758, 1135
Mutagenesis-validated functional residues (3):
| Position | Phenotype |
|---|---|
| 1254 | does not abolish the interaction with rab11a, homooligomerization and subcellular location. reduces the interaction with |
| 1255 | abolishes the interaction with rab11a, rab4a and rab14, homooligomerization and subcellular location. |
| 1256 | does not abolish the interaction with rab11a, homooligomerization and subcellular location. reduces the interaction with |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 278 (showing top):
GGGACCA_MIR133A_MIR133B, PEREZ_TP63_TARGETS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOMF_GTPASE_BINDING, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_CELL_CELL_SIGNALING, PATIL_LIVER_CANCER, GTGCCTT_MIR506, GOBP_REGULATION_OF_PROTEIN_SECRETION, GOBP_EXOCYTOSIS, OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT
GO Biological Process (3): protein transport (GO:0015031), regulated exocytosis (GO:0045055), negative regulation of adiponectin secretion (GO:0070164)
GO Molecular Function (2): small GTPase binding (GO:0031267), protein binding (GO:0005515)
GO Cellular Component (7): cytosol (GO:0005829), phagocytic vesicle membrane (GO:0030670), recycling endosome (GO:0055037), cytoplasm (GO:0005737), endosome (GO:0005768), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| cytoplasm | 2 |
| transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| exocytosis | 1 |
| negative regulation of hormone secretion | 1 |
| negative regulation of protein secretion | 1 |
| negative regulation of multicellular organismal process | 1 |
| adiponectin secretion | 1 |
| regulation of adiponectin secretion | 1 |
| GTPase binding | 1 |
| binding | 1 |
| endocytic vesicle membrane | 1 |
| phagocytic vesicle | 1 |
| endosome | 1 |
| intracellular anatomical structure | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| intracellular vesicle | 1 |
Protein interactions and networks
STRING
1823 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RAB11FIP1 | RAB11A | P24410 | 987 |
| RAB11FIP1 | RAB25 | P57735 | 974 |
| RAB11FIP1 | RAB4A | P20338 | 952 |
| RAB11FIP1 | RAB11FIP3 | O75154 | 939 |
| RAB11FIP1 | RAB11FIP4 | Q86YS3 | 932 |
| RAB11FIP1 | MYO5B | Q9ULV0 | 848 |
| RAB11FIP1 | ARF5 | P26437 | 735 |
| RAB11FIP1 | RAB1A | P11476 | 633 |
| RAB11FIP1 | PLPBP | O94903 | 613 |
| RAB11FIP1 | ARF6 | P26438 | 609 |
| RAB11FIP1 | EXOC7 | Q9UPT5 | 584 |
| RAB11FIP1 | RAB14 | P35287 | 565 |
| RAB11FIP1 | LETM2 | Q2VYF4 | 543 |
| RAB11FIP1 | DDHD2 | O94830 | 532 |
| RAB11FIP1 | ERLIN2 | O94905 | 518 |
IntAct
94 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| IKBKG | IKBKB | psi-mi:“MI:0914”(association) | 0.980 |
| RAB11A | EVI5 | psi-mi:“MI:0914”(association) | 0.800 |
| YWHAH | ABLIM1 | psi-mi:“MI:0914”(association) | 0.800 |
| YWHAB | PIK3C2A | psi-mi:“MI:0914”(association) | 0.800 |
| RAB11FIP1 | YWHAH | psi-mi:“MI:0914”(association) | 0.740 |
| KLC1 | KIF5B | psi-mi:“MI:0914”(association) | 0.730 |
| CFTR | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.710 |
| CTBP2 | ZNF217 | psi-mi:“MI:0914”(association) | 0.690 |
| YWHAG | BLTP3B | psi-mi:“MI:0914”(association) | 0.640 |
| YWHAG | BLTP3B | psi-mi:“MI:2364”(proximity) | 0.640 |
| RAB11B | SH3BP5 | psi-mi:“MI:0914”(association) | 0.640 |
| MMAB | DBT | psi-mi:“MI:0914”(association) | 0.620 |
| RAB11A | CHML | psi-mi:“MI:2364”(proximity) | 0.610 |
| YWHAH | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.610 |
| YWHAB | BLTP3B | psi-mi:“MI:2364”(proximity) | 0.610 |
| YWHAB | BLTP3B | psi-mi:“MI:0914”(association) | 0.610 |
| YWHAE | PIK3C2A | psi-mi:“MI:0914”(association) | 0.570 |
| YWHAH | BLTP3B | psi-mi:“MI:0914”(association) | 0.570 |
| YWHAH | BLTP3B | psi-mi:“MI:2364”(proximity) | 0.570 |
| BAIAP2 | WASL | psi-mi:“MI:0914”(association) | 0.550 |
| RAB11A | SH3BP5 | psi-mi:“MI:0914”(association) | 0.530 |
| YWHAB | PLEKHG3 | psi-mi:“MI:0914”(association) | 0.480 |
| RAB11FIP1 | PASK | psi-mi:“MI:0217”(phosphorylation reaction) | 0.440 |
| RAB11A | LANCL1 | psi-mi:“MI:2364”(proximity) | 0.420 |
| SEC24B | RAB11FIP1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| Rab11a | EVI5 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (195): RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), ASAP1 (Affinity Capture-Western), RAB11FIP1 (Proximity Label-MS), RAB11FIP1 (Proximity Label-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS), RAB11FIP1 (Affinity Capture-MS)
ESM2 similar proteins: A2A995, A2ALU4, A4IGN8, A6NMK8, D3ZUI5, E1C2Q8, F1QGH6, O54931, O75128, O75363, O75410, O95425, P24275, P24588, P51827, Q1LWM5, Q1RMS0, Q1W617, Q3UHI0, Q3UMF0, Q3ZB98, Q499V8, Q53SF7, Q5JR59, Q5NBX1, Q5VWT5, Q5ZJ26, Q62394, Q66KC9, Q673G8, Q69ZL1, Q6GQV1, Q6INC4, Q6QZN6, Q6WKZ4, Q6Y685, Q7TP36, Q7TS75, Q80YN3, Q8BI29
Diamond homologs: C9J798, G3XA57, O43374, O95294, P41823, Q3B7T9, Q6DN14, Q6PFQ7, Q6WKZ4, Q7L804, Q8R361, Q9BXF6, Q9D620, Q9SKA3, Q9ZVT9, Q4KUS2, Q62768, Q62769, Q62770, Q8K0T7, Q8NB66, Q9UPW8, Q9Z1N9, O35681, P41885
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| MARK2 | “up-regulates quantity” | RAB11FIP1 | phosphorylation |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 94 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Activation of BAD and translocation to mitochondria | 7 | 78.4× | 3e-10 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 7 | 69.2× | 5e-10 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 7 | 69.2× | 5e-10 |
| Activation of BH3-only proteins | 7 | 51.1× | 4e-09 |
| RHO GTPases activate PKNs | 7 | 32.7× | 1e-07 |
| Intrinsic Pathway for Apoptosis | 7 | 30.1× | 2e-07 |
| FOXO-mediated transcription | 5 | 24.7× | 4e-05 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 8 | 18.2× | 5e-07 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| protein targeting | 5 | 22.1× | 1e-03 |
| intracellular protein localization | 9 | 11.3× | 8e-05 |
| protein autophosphorylation | 6 | 10.5× | 5e-03 |
| positive regulation of ERK1 and ERK2 cascade | 7 | 7.2× | 7e-03 |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 7 | 6.6× | 8e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
214 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 178 |
| Likely benign | 16 |
| Benign | 5 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1302 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:37862956:T:TA | donor_gain | 1.0000 |
| 8:37870415:CATA:C | donor_loss | 1.0000 |
| 8:37870416:ATAC:A | donor_loss | 1.0000 |
| 8:37870418:A:C | donor_loss | 1.0000 |
| 8:37870419:C:G | donor_loss | 1.0000 |
| 8:37870529:C:CC | acceptor_gain | 1.0000 |
| 8:37875318:CATGA:C | acceptor_gain | 1.0000 |
| 8:37875319:ATGA:A | acceptor_gain | 1.0000 |
| 8:37875320:TGA:T | acceptor_gain | 1.0000 |
| 8:37875323:C:CC | acceptor_gain | 1.0000 |
| 8:37875324:T:C | acceptor_gain | 1.0000 |
| 8:37875325:T:C | acceptor_gain | 1.0000 |
| 8:37875325:T:TC | acceptor_gain | 1.0000 |
| 8:37877104:CTCA:C | donor_loss | 1.0000 |
| 8:37877105:TCA:T | donor_loss | 1.0000 |
| 8:37877106:CACC:C | donor_loss | 1.0000 |
| 8:37877107:A:AC | donor_gain | 1.0000 |
| 8:37877107:A:T | donor_loss | 1.0000 |
| 8:37877107:AC:A | donor_gain | 1.0000 |
| 8:37877107:ACCAT:A | donor_gain | 1.0000 |
| 8:37877108:C:CA | donor_gain | 1.0000 |
| 8:37877108:CC:C | donor_gain | 1.0000 |
| 8:37877108:CCAT:C | donor_gain | 1.0000 |
| 8:37877108:CCATC:C | donor_gain | 1.0000 |
| 8:37899066:CTCA:C | donor_gain | 1.0000 |
| 8:37899069:A:AC | donor_gain | 1.0000 |
| 8:37899069:ACTG:A | donor_gain | 1.0000 |
| 8:37899070:C:CG | donor_gain | 1.0000 |
| 8:37899070:CTG:C | donor_gain | 1.0000 |
| 8:37899070:CTGC:C | donor_gain | 1.0000 |
AlphaMissense
8351 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:37862974:A:G | L1258P | 1.000 |
| 8:37899244:C:A | W66C | 1.000 |
| 8:37899244:C:G | W66C | 1.000 |
| 8:37899246:A:G | W66R | 1.000 |
| 8:37899246:A:T | W66R | 1.000 |
| 8:37862971:A:G | L1259P | 0.999 |
| 8:37862995:A:G | L1251P | 0.999 |
| 8:37863058:A:G | L1230P | 0.999 |
| 8:37877480:A:G | F148S | 0.999 |
| 8:37877492:A:T | V144D | 0.999 |
| 8:37877498:A:T | I142N | 0.999 |
| 8:37877505:C:G | G140R | 0.999 |
| 8:37877505:C:T | G140R | 0.999 |
| 8:37877540:A:G | L128S | 0.999 |
| 8:37899128:C:T | G105D | 0.999 |
| 8:37899129:C:G | G105R | 0.999 |
| 8:37899133:G:C | F103L | 0.999 |
| 8:37899133:G:T | F103L | 0.999 |
| 8:37899134:A:G | F103S | 0.999 |
| 8:37899135:A:G | F103L | 0.999 |
| 8:37899140:T:A | D101V | 0.999 |
| 8:37899173:A:G | L90P | 0.999 |
| 8:37899227:A:G | F72S | 0.999 |
| 8:37899245:C:G | W66S | 0.999 |
| 8:37899318:A:C | Y42D | 0.999 |
| 8:37862962:A:T | V1262D | 0.998 |
| 8:37863049:A:G | L1233P | 0.998 |
| 8:37877504:C:A | G140V | 0.998 |
| 8:37877504:C:T | G140E | 0.998 |
| 8:37877540:A:C | L128W | 0.998 |
dbSNP variants (sampled 300 via entrez): RS1000112202 (8:37878097 G>A,C), RS1000196590 (8:37898883 G>A,C,T), RS1000295767 (8:37877904 G>A,C), RS1000472151 (8:37861422 A>G), RS1000572142 (8:37861156 G>A), RS1000646840 (8:37896585 T>C), RS1000651405 (8:37899658 G>A,T), RS1000761431 (8:37899563 A>C,G,T), RS1000872124 (8:37890706 C>T), RS1000892933 (8:37866110 C>A,G,T), RS1000932782 (8:37872512 C>T), RS1000998571 (8:37859673 G>A,C), RS1001198966 (8:37900637 C>T), RS1001347322 (8:37888693 G>C), RS1001454580 (8:37868859 C>T)
Disease associations
OMIM: gene MIM:608737 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002115_11 | Axial length | 3.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0005318 | axial length measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
71 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases abundance, increases expression | 4 |
| Valproic Acid | increases expression, affects expression | 4 |
| Estradiol | decreases expression, increases expression | 3 |
| Smoke | decreases expression | 3 |
| Tobacco Smoke Pollution | affects expression, increases expression | 3 |
| methylmercuric chloride | increases expression | 2 |
| bisphenol A | increases reaction, decreases expression, affects binding | 2 |
| trichostatin A | affects expression, increases expression | 2 |
| Calcitriol | increases expression, affects cotreatment | 2 |
| Doxorubicin | decreases expression, affects response to substance | 2 |
| Phenylmercuric Acetate | affects cotreatment, increases expression | 2 |
| aristolochic acid I | increases expression | 1 |
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| FR900359 | affects phosphorylation | 1 |
| ethylbenzene | increases methylation, affects cotreatment, decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenate | decreases expression | 1 |
| decabromobiphenyl ether | decreases expression | 1 |
| butyraldehyde | increases expression | 1 |
| tetrabromobisphenol A | decreases expression | 1 |
| potassium chromate(VI) | decreases expression | 1 |
| coumarin | decreases phosphorylation | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| entinostat | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | increases expression, affects cotreatment | 1 |
| erucylphospho-N,N,N-trimethylpropylammonium | increases expression | 1 |
| nutlin 3 | increases secretion, affects cotreatment | 1 |
| 2,2’,4,4’-tetrabromodiphenyl ether | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.